Hypoglycaemia: recognising low blood glucose — AU general practice guide

What low blood glucose actually means

Hypoglycaemia is blood glucose that has fallen low enough to impair normal brain function. The brain stores virtually no glucose; within minutes of levels dropping below 3 mmol/L, cognition falters, and below 2.5 mmol/L the risk of seizure and loss of consciousness rises sharply.

The Australasian Diabetes Society (ADS) and American Diabetes Association (ADA Standards of Care 2024) classify hypoglycaemia in diabetes by plasma glucose level: Level 1 is 3.0–3.9 mmol/L — the alert value where physiological counter-regulation begins and where treatment should start; Level 2 is below 3.0 mmol/L, where cognitive impairment is imminent; Level 3 (severe) is any episode requiring assistance from another person, regardless of the glucose reading.

In everyday general practice, hypoglycaemia is overwhelmingly a complication of diabetes treatment. Insulin and sulfonylurea medicines (gliclazide, glimepiride) account for the vast majority of episodes. Uncommonly, it occurs in people without diabetes and without glucose-lowering treatment — and in those cases it always warrants thorough investigation, not reassurance.

A. Core clinical — the AU general-practice framework

Symptoms: two tiers

Symptoms emerge in two distinct tiers driven by different physiology.

Autonomic (3.0–3.9 mmol/L): sweating, palpitations, tremor, hunger, anxiety, and tingling around the lips and fingertips. These are the body’s early warning system. Critically, people who experience frequent hypoglycaemia may lose these warnings — a phenomenon called hypoglycaemia unawareness — and may progress directly to neuroglycopenic impairment without recognising the problem. Recurrent severe episodes can cause cardiac arrhythmia, including “dead-in-bed” syndrome in type 1 diabetes.

Neuroglycopenic (below 3.0 mmol/L): cognitive slowing, confusion, dizziness, slurred speech, blurred or double vision, behavioural change, focal neurological deficit, seizure, and coma.

Common causes in people with diabetes

The RACGP / Diabetes Australia Type 2 Diabetes Handbook 2024 identifies the main drivers presenting in general practice:

• Insulin — mismatch between dose and carbohydrate intake or physical activity; injection into a site of lipohypertrophy causing unpredictable absorption; stacking of correction boluses without checking the previous dose has worn off
• Sulfonylureas (gliclazide, glimepiride) — especially in people with kidney impairment (prolonged drug half-life) and older adults; sulfonylurea-driven hypoglycaemia typically lasts 12–24 hours because the drug continues stimulating insulin release even after glucose has been corrected
• Missed or delayed meals after dosing
• Unplanned or prolonged exercise, particularly where basal insulin was not pre-emptively reduced
• Alcohol — suppresses hepatic gluconeogenesis; typically produces delayed nocturnal hypoglycaemia hours after drinking
• Intercurrent illness — reduced food intake, vomiting, or diarrhoea altering absorption and intake
• Renal or hepatic impairment — reduces clearance of insulin and sulfonylureas and reduces the liver’s gluconeogenic reserve

Acute treatment: the 15-g rule

Per eTG Diabetic emergencies and ADS position statements:

Conscious person, able to swallow safely: Take 15 g of rapid-acting carbohydrate — approximately 200 mL of regular (not diet) fruit juice, six to seven jelly beans, three glucose tablets, one tablespoon of table sugar, or one tablespoon of honey. Recheck capillary glucose at 15 minutes. If still below 4 mmol/L, repeat the 15 g. Once above 4 mmol/L, follow immediately with a complex carbohydrate meal or snack (bread, crackers, milk, or fruit) to prevent a second fall — essential after sulfonylurea-induced hypoglycaemia or long-acting insulin.

Conscious but impaired, airway protected, cannot cooperate: Buccal glucose gel (GlucoGel) — one to two tubes massaged inside the cheek against the gum. Recheck glucose at 10–15 minutes. Never force oral intake if the swallow is unsafe.

Unconscious or unable to swallow — call 000:

• Glucagon 1 mg IM or SC (GlucaGen HypoKit) — inject into the outer thigh; can be given through light clothing
• Intranasal glucagon 3 mg (Baqsimi) — one puff into one nostril; nasal congestion does not impair absorption; no needle reconstitution, making this the preferred option for lay rescuers

Both work within 5–15 minutes in glycogen-replete individuals. Glucagon is less effective in people who are malnourished, have liver disease, or drink heavily — their glycogen stores are depleted. In these situations, intravenous glucose is required.

With IV access (hospital or paramedics): Per eTG: 10% glucose 100–150 mL IV over 10–15 minutes (lower phlebitis risk than 50% dextrose) or 50% glucose 25–50 mL via a large vein with care to avoid extravasation. Follow with a 10% glucose infusion at 100 mL/hour if hypoglycaemia recurs.

Sulfonylurea-specific: Admit and observe for at least 24 hours. Maintain 10% glucose IV infusion. For refractory cases, octreotide 50–100 mcg SC every 6–12 hours suppresses ongoing sulfonylurea-driven insulin secretion per the AMH.

Long-term prevention in diabetes

The core prevention bundle for any person on insulin or a sulfonylurea — per RACGP/Diabetes Australia and NPS MedicineWise:

• Written sick-day plan reviewed annually
• Structured education on symptom recognition, treatment steps, and dose adjustment
• CGM with low-glucose alarm below 4 mmol/L where NDSS-eligible
• Family and carer training in glucagon administration; refresh kit before expiry
• MedicAlert bracelet for every person on insulin or a sulfonylurea
• Driving compliance per Austroads (see Section D)
• Supplement review — herbal supplements marketed for blood glucose (cinnamon, bitter melon, gymnema) carry additive hypoglycaemia risk with insulin and sulfonylureas

B. Evidence — prevention strategies that work

Continuous glucose monitoring

The DIAMOND trial (Beck, JAMA 2017) established that CGM with a low-glucose alert significantly reduces time spent in hypoglycaemia and lowers the rate of severe episodes in type 1 and intensive-insulin type 2 diabetes. Setting the alarm at below 4 mmol/L gives time to act before neuroglycopenic symptoms appear.

The NDSS now funds CGM sensors for all Australians with type 1 diabetes (since July 2022) and selected people with type 2 diabetes on insulin who have hypoglycaemia unawareness, are pregnant, or hold a concession card. Supported devices include the Dexcom G6/G7 and FreeStyle Libre 2/3. For those with unawareness, a period of strict hypoglycaemia avoidance of 2–4 weeks — supported by CGM alarms and adjusted insulin targets — can partially restore autonomic warning symptoms, giving the body the opportunity to recalibrate its counter-regulatory threshold.

Hybrid closed-loop insulin delivery

The Brown et al. N Engl J Med 2019 trial of a hybrid closed-loop system — automated insulin delivery responding to real-time CGM data — showed improved time-in-range and significantly reduced hypoglycaemia compared with sensor-augmented pump therapy in type 1 diabetes. Devices (Tandem t:slim with Control-IQ, Medtronic 780G, Omnipod 5) are increasingly funded through the NDSS Insulin Pump Program for eligible adults and children with type 1 diabetes.

Sulfonylurea deprescribing in older adults

Lipska et al. JAMA Intern Med 2017 found that sulfonylurea-related hypoglycaemia drives emergency department presentations, falls, fractures, and death in older adults — often in patients whose targets could be safely relaxed. The RACGP/Diabetes Australia Handbook 2024 endorses switching to DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists in patients aged 75 and over, those with eGFR below 45, or anyone with a history of hypoglycaemia.

Individualising HbA1c targets

The ACCORD trial (N Engl J Med 2008) found that intensive glycaemic control targeting HbA1c below 6% in older adults with established cardiovascular disease tripled the rate of severe hypoglycaemia and increased all-cause mortality. The lesson embedded in Australian guidelines: in older adults, those with cardiovascular disease, frailty, or any prior hypoglycaemia, relax the HbA1c target to 7.5–8% by shared decision-making rather than pursuing the lowest achievable number.

C. Non-diabetic hypoglycaemia — investigation approach

Hypoglycaemia in someone not on insulin or a sulfonylurea is uncommon in general practice and always warrants formal investigation. The Endocrine Society 2009 guideline on adult hypoglycaemic disorders requires Whipple’s triad before proceeding: (1) symptoms consistent with hypoglycaemia, (2) documented low plasma glucose at the time of symptoms, and (3) resolution of symptoms when glucose rises. A single symptomatic episode with a borderline glucose on a home monitor does not constitute Whipple’s triad — laboratory confirmation matters.

Non-diabetic causes to consider:

• Drug-induced — alcohol (suppresses hepatic gluconeogenesis; presents nocturnally hours after drinking), quinine, pentamidine, surreptitious use of insulin or a sulfonylurea, IGF-2 secreting compounds
• Critical illness — sepsis, hepatic failure, severe renal impairment, cardiac failure, malignancy
• Hormonal deficiency — adrenal insufficiency (consider in anyone with fatigue, postural hypotension, and unexplained hypoglycaemia), hypopituitarism
• Endogenous hyperinsulinism — insulinoma, an insulin-secreting pancreatic neuroendocrine tumour (95% benign, usually solitary; consider MEN-1 syndrome if multiple endocrine tumours); nesidioblastosis (diffuse beta-cell hyperplasia); insulin autoantibody syndrome
• Post-bariatric reactive hypoglycaemia — occurs 1–3 hours after meals in a significant minority of Roux-en-Y gastric bypass patients, driven by exaggerated incretin and insulin responses; managed with low glycaemic index, small frequent, low-carbohydrate meals as first-line dietary approach

Investigation pathway when Whipple’s triad is met:

Draw a simultaneous sample for plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, cortisol, and a sulfonylurea/meglitinide screen at the time of symptoms. If the episode was not witnessed or sampled in real time, arrange a supervised 72-hour fast with 6-hourly sampling, terminated when plasma glucose falls to 2.5 mmol/L with symptoms. A pattern of low glucose + inappropriately elevated insulin + elevated C-peptide + suppressed beta-hydroxybutyrate + negative sulfonylurea screen points to endogenous hyperinsulinism and warrants specialist referral for pancreatic MRI and endoscopic ultrasound.

D. Australian operations

NDSS registration is the starting point for every person with diabetes. The National Diabetes Services Scheme (1800 637 700) subsidises blood glucose strips, ketone strips, CGM sensors, and insulin pump consumables. Registration is free and can be completed via any accredited prescriber; the treating GP or credentialled diabetes educator can assist.

PBS medicines relevant to hypoglycaemia management:

• Gliclazide and glimepiride: General Schedule
• DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists: Authority prescription for type 2 diabetes
• Glucagon IM kit (GlucaGen HypoKit) and intranasal glucagon (Baqsimi): PBS Authority Streamlined for diabetes — ensure every eligible patient holds a current kit and carers know how to use it
• Diazoxide and octreotide for insulinoma or refractory sulfonylurea hypoglycaemia: specialist Authority prescriptions

MBS items for chronic diabetes management with hypoglycaemia:

• GP standard consultations: items 23, 36, and 44
• Chronic disease management plan (GPMP/TCA): items 721 and 723
• Complex care (GPCCMP) for diabetes with complications: items 965 and 967 — five allied health visits per year (ten for ATSI patients) covering dietitian, credentialled diabetes educator, exercise physiologist, and podiatrist
• ATSI Health Assessment: item 715
• Mental Health Care Plan for diabetes distress, diabulimia, or comorbid anxiety or depression: items 2715 and 2717

Driving and Austroads compliance. The Austroads Assessing Fitness to Drive 2022 standard requires every person on insulin or a sulfonylurea to: check blood glucose to at least 5 mmol/L before driving; recheck every 2 hours on long trips; keep rapid carbohydrate accessible in the vehicle; stop driving if glucose drops below 5 mmol/L; and wait at least 45 minutes after treating a hypo before resuming. Commercial licence holders face substantially stricter requirements and specialist review. A severe hypoglycaemia event while driving may require notification to the relevant state licensing authority. This conversation should be documented in the medical record at each relevant review.

MedicAlert. MedicAlert bracelets allow emergency responders and bystanders to identify the condition and treatment when the person is found unconscious. This identification step can be life-saving.

E. Special populations

Older adults. Hypoglycaemia in older adults is more dangerous across every dimension — impaired autonomic warning from reduced adrenergic response, higher fall and fracture risk, cognitive vulnerability at smaller glucose changes, and prolonged sulfonylurea half-life from age-related renal decline. The clinical priority is removing high-risk agents before tightening any target. Deprescribe sulfonylureas in any patient aged 75 or over, eGFR below 45, or any prior hypoglycaemia history; switch to a DPP-4 inhibitor as the lowest-risk oral agent. Relax HbA1c target to 7.5–8% by shared agreement. CGM with a low-glucose alarm is particularly valuable in those with unawareness where autonomic warnings can no longer be relied upon.

Pregnancy. Type 1 diabetes in pregnancy carries the highest hypoglycaemia burden of any group — hormonal changes alter insulin sensitivity substantially across each trimester, and guidelines recommend setting CGM low-glucose alerts at 3.5 mmol/L to protect the foetus. Hybrid closed-loop systems are increasingly used throughout pregnancy. Type 2 diabetes on insulin during pregnancy also requires specialist-led dose adjustment, especially in the first trimester when insulin requirements often fall. All insulin-treated diabetes in pregnancy should be co-managed by an endocrinologist and credentialled diabetes educator from the outset.

Aboriginal and Torres Strait Islander Australians. Type 2 diabetes carries disproportionate burden in ATSI communities, and hypoglycaemia risk is amplified by higher prevalence of renal disease (which prolongs sulfonylurea action) and factors affecting consistent meal access. Coordinate care via Aboriginal Health Workers and Aboriginal community controlled health organisations. MBS item 715 (ATSI Health Assessment) and the GPCCMP (items 965 and 967) support structured allied health access — dietitian, credentialled diabetes educator, and exercise physiologist — and should be activated proactively.

Post-bariatric surgery. Reactive hypoglycaemia after Roux-en-Y gastric bypass occurs 1–3 hours post-meal in a significant subset of patients. First-line management is dietary: small frequent meals, low glycaemic index, low simple carbohydrate, with the gut-motility modifier acarbose as adjunct where diet alone is insufficient. A dietitian experienced in bariatric nutrition is central to management. Rarely, specialist-supervised diazoxide or octreotide is required; surgical revision is a last resort.

Eating disorders and diabulimia. Deliberate insulin omission — diabulimia — in young people with type 1 diabetes creates erratic glycaemia, including hypoglycaemia during unplanned corrections. These patients need co-management by a specialist eating disorder team and diabetes team. A Mental Health Care Plan (items 2715 and 2717) should be activated early alongside specialist referral.

Children and adolescents. Paediatric type 1 diabetes management aims to avoid nocturnal hypoglycaemia especially, as children may not wake to warning symptoms. Closed-loop insulin delivery and CGM with nighttime alarms are standard-of-care in this group. Parents and school staff should be trained in glucagon administration and have a current glucagon kit available.

When to escalate

Refer or escalate when:

• Unconscious, seizing, or unresponsive — 000 immediately; admit for monitoring and cause review
• Sulfonylurea-induced hypoglycaemia requiring more than one correction, or recurrence after the first treatment — admit for at least 24-hour observation and IV glucose
• Recurrent unexplained hypoglycaemia — systematic review of all medicines, renal and hepatic function, and intercurrent illness; endocrinology referral
• Hypoglycaemia unawareness not improving after a structured avoidance period with CGM support — specialist diabetes service referral
• Whipple’s triad met in a non-diabetic person — arrange supervised 72-hour fast and specialist endocrinology review
• Suspected insulinoma — urgent specialist referral for pancreatic imaging and surgical planning
• Post-bariatric reactive hypoglycaemia not responding to dietary measures — bariatric specialist referral
• All insulin-treated diabetes in pregnancy — specialist co-management from the outset

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — RACGP / Diabetes Australia Handbook 2024, Therapeutic Guidelines (eTG), Australian Medicines Handbook (AMH), NPS MedicineWise, ADS position statements, and Austroads Fitness to Drive 2022. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about glucose targets, medicine choices, CGM access, and driving fitness are made with your own GP and treating clinicians.

For Australian consumer resources: Diabetes Australia, NDSS 1800 637 700, HealthDirect 1800 022 222, Better Health Channel, MedicAlert Australia.

For an emergency: call 000.

---

Sources cited

1. RACGP / Diabetes Australia — Type 2 Diabetes Handbook 2024
2. Australasian Diabetes Society — Position Statements
3. Therapeutic Guidelines (eTG) — Diabetic emergencies
4. Australian Medicines Handbook (AMH)
5. NPS MedicineWise
6. Austroads — Assessing Fitness to Drive 2022
7. NDSS — National Diabetes Services Scheme
8. Diabetes Australia
9. HealthDirect — Hypoglycaemia
10. Better Health Channel — Hypoglycaemia
11. MedicAlert Australia
12. Endocrine Society 2009 — Evaluation and Management of Adult Hypoglycaemic Disorders
13. ADA Standards of Care in Diabetes 2024
14. Beck et al. — DIAMOND CGM in type 1 diabetes (JAMA 2017)
15. Lipska et al. — Sulfonylurea hypoglycaemia in elderly (JAMA Intern Med 2017)
16. Brown et al. — Hybrid closed-loop in type 1 diabetes (N Engl J Med 2019)
17. ACCORD trial — intensive glycaemic control (N Engl J Med 2008)